Capricor Therapeutics $CAPR claimed its miracle drug for Duchenne muscular dystrophy was cruising toward FDA approval. But behind the scenes? Alleged data concealment, canceled advisory meetings, and a crushing FDA rejection. In this episode of Sue Wall Street, Cassie and Bill unravel the class action lawsuit and the biotech optimism that may have misled investors. If you're a biotech investor, retail trader, or class action watcher this one’s for you. Expect sharp analysis, spicy quotes, and no sugarcoating.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.